Login
$ENVB
$1.44 -$0.07 (4.95%) Live

$ENVB SEC Filings

Filed On Filing
13 Nov 2026 10-Q
13 Nov 2026 8-K: Results of Operations and Financial Condition
03 Nov 2026 SCHEDULE 13G
14 Aug 2026 10-Q
14 Aug 2026 8-K: Results of Operations and Financial Condition

Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G
13 Aug 2026 SCHEDULE 13G/A
09 Jun 2026 8-K: Other Events

Registration Statement on Form S-3 Enveric Biosciences, Inc.

09 Jun 2026 424B5
09 Jun 2026 8-K: Regulation FD Disclosure

Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about June 8, 2026. From time to time thereafter, the Company may use the...

03 Jun 2026 Form 4: Coveney Kevin Michael, Chief Financial Officer

Received 133,333 shares as a grant or award

03 Jun 2026 Form 4: Tucker Joseph Edward, Director

Received 201,124 shares as a grant or award

03 Jun 2026 Form 4: Pasqualone Frank, Director

Received 18,518 shares as a grant or award

03 Jun 2026 Form 4: Webb Michael D, Director

Received 18,518 shares as a grant or award

03 Jun 2026 Form 4: Schabacker Marcus, Director

Received 18,518 shares as a grant or award

03 Jun 2026 Form 4: Kegler George A., Director

Received 18,518 shares as a grant or award

03 Jun 2026 Form 4: DeWitt Sheila, Director

Received 18,518 shares as a grant or award

03 Jun 2026 Form 4: Facchini Peter J., Chief Innovation Officer

Received 25,000 shares as a grant or award

01 Jun 2026 S-8

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support